Literature DB >> 20385751

Milestones in progression of primary pneumonic plague in cynomolgus macaques.

Frederick Koster1, David S Perlin, Steven Park, Trevor Brasel, Andrew Gigliotti, Edward Barr, Leslie Myers, Robert C Layton, Robert Sherwood, C R Lyons.   

Abstract

Vaccines against primary pneumonic plague, a potential bioweapon, must be tested for efficacy in well-characterized nonhuman primate models. Telemetered cynomolgus macaques (Macaca fascicularis) were challenged by the aerosol route with doses equivalent to approximately 100 50% effective doses of Yersinia pestis strain CO92 and necropsied at 24-h intervals postexposure (p.e.). Data for telemetered heart rates, respiratory rates, and increases in the temperature greater than the diurnal baseline values identified the onset of the systemic response at 55 to 60 h p.e. in all animals observed for at least 70 h p.e. Bacteremia was detected at 72 h p.e. by a Yersinia 16S rRNA-specific quantitative reverse transcription-PCR and was detected later by the culture method at the time of moribund necropsy. By 72 h p.e. multilobar pneumonia with diffuse septal inflammation consistent with early bacteremia was established, and all lung tissues had a high bacterial burden. The levels of cytokines or chemokines in serum were not significantly elevated at any time, and only the interleukin-1beta, CCL2, and CCL3 levels were elevated in lung tissue. Inhalational plague in the cynomolgus macaque inoculated by the aerosol route produces most clinical features of the human disease, and in addition the disease progression mimics the disease progression from the anti-inflammatory phase to the proinflammatory phase described for the murine model. Defined milestones of disease progression, particularly the onset of fever, tachypnea, and bacteremia, should be useful for evaluating the efficacy of candidate vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20385751      PMCID: PMC2897392          DOI: 10.1128/IAI.01296-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

Review 1.  Molecular and cell biology aspects of plague.

Authors:  G R Cornelis
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

2.  Plague immunization. IV. Clinical reactions and serologic response to inoculations of Haffkine and freeze-dried plague vaccine.

Authors:  K F Meyer; G Smith; L E Foster; J D Marshall; D C Cavanaugh
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

3.  Studies on the pathogenesis of plague. Blood coagulation and tissue responses of Macaca mulatta following exposure to aerosols of Pasteurella pestis.

Authors:  M J Finegold; J J Petery; R F Berendt; H R Adams
Journal:  Am J Pathol       Date:  1968-07       Impact factor: 4.307

4.  Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops).

Authors:  K J Davis; D L Fritz; M L Pitt; S L Welkos; P L Worsham; A M Friedlander
Journal:  Arch Pathol Lab Med       Date:  1996-02       Impact factor: 5.534

5.  Pneumonic plague in an untreated plague-vaccinated individual.

Authors:  R J Cohen; J L Stockard
Journal:  JAMA       Date:  1967-10-23       Impact factor: 56.272

6.  Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar.

Authors:  M Ratsitorahina; S Chanteau; L Rahalison; L Ratsifasoamanana; P Boisier
Journal:  Lancet       Date:  2000-01-08       Impact factor: 79.321

Review 7.  Yersinia pestis--etiologic agent of plague.

Authors:  R D Perry; J D Fetherston
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

8.  Primary plague pneumonia contracted from a domestic cat at South Lake Tahoe, Calif.

Authors:  S B Werner; C E Weidmer; B C Nelson; G S Nygaard; R M Goethals; J D Poland
Journal:  JAMA       Date:  1984-02-17       Impact factor: 56.272

9.  Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona.

Authors:  J M Doll; P S Zeitz; P Ettestad; A L Bucholtz; T Davis; K Gage
Journal:  Am J Trop Med Hyg       Date:  1994-07       Impact factor: 2.345

10.  Clinical and pathologic features of cynomolgus macaques (Macaca fascicularis) infected with aerosolized Yersinia pestis.

Authors:  Roger Van Andel; Robert Sherwood; Chris Gennings; C Richard Lyons; Julie Hutt; Andrew Gigliotti; Ed Barr
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

View more
  20 in total

1.  Pulmonary infection by Yersinia pestis rapidly establishes a permissive environment for microbial proliferation.

Authors:  Paul A Price; Jianping Jin; William E Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-01       Impact factor: 11.205

2.  Primary pneumonic plague in the African Green monkey as a model for treatment efficacy evaluation.

Authors:  R Colby Layton; Trevor Brasel; Andrew Gigliotti; Edward Barr; Steven Storch; Leslie Myers; Charles Hobbs; Frederick Koster
Journal:  J Med Primatol       Date:  2010-08-16       Impact factor: 0.667

3.  Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.

Authors:  Lauriane E Quenee; Nancy A Ciletti; Derek Elli; Timothy M Hermanas; Olaf Schneewind
Journal:  Vaccine       Date:  2011-07-16       Impact factor: 3.641

4.  Remote monitoring of the progression of primary pneumonic plague in Brown Norway rats in high-capacity, high-containment housing.

Authors:  Eric A Coate; Andrew G Kocsis; Kristen N Peters; Paul E Anderson; Mark R Ellersieck; Deborah M Fine; Deborah M Anderson
Journal:  Pathog Dis       Date:  2014-05-16       Impact factor: 3.166

5.  Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.

Authors:  Jason A Rosenzweig; Sheri M Brackman; Michelle L Kirtley; Jian Sha; Tatiana E Erova; Linsey A Yeager; Johnny W Peterson; Ze-Qi Xu; Ashok K Chopra
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

6.  A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.

Authors:  Jian Sha; Michelle L Kirtley; Curtis Klages; Tatiana E Erova; Maxim Telepnev; Duraisamy Ponnusamy; Eric C Fitts; Wallace B Baze; Satheesh K Sivasubramani; William S Lawrence; Igor Patrikeev; Jennifer E Peel; Jourdan A Andersson; Elena V Kozlova; Bethany L Tiner; Johnny W Peterson; David McWilliams; Snehal Patel; Eric Rothe; Vladimir L Motin; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

7.  Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.

Authors:  William Bowen; Lalit Batra; Amanda R Pulsifer; Esma S Yolcu; Matthew B Lawrenz; Haval Shirwan
Journal:  Vaccine       Date:  2019-08-12       Impact factor: 3.641

8.  The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule.

Authors:  Judith A Hewitt; Lynda L Lanning; Joseph L Campbell
Journal:  Clin Infect Dis       Date:  2020-05-21       Impact factor: 9.079

9.  A Dual Role for the Plasminogen Activator Protease During the Preinflammatory Phase of Primary Pneumonic Plague.

Authors:  Srijon K Banerjee; Samantha D Crane; Roger D Pechous
Journal:  J Infect Dis       Date:  2020-07-06       Impact factor: 5.226

10.  Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaques.

Authors:  Qingwen Zhang; Qiong Wang; Guang Tian; Zhizhen Qi; Xuecan Zhang; Xiaohong Wu; Yefeng Qiu; Yujing Bi; Xiaoyan Yang; Youquan Xin; Jian He; Jiyuan Zhou; Lin Zeng; Ruifu Yang; Xiaoyi Wang
Journal:  Hum Vaccin Immunother       Date:  2013-11-13       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.